Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2013

01-12-2013 | Pediatrics (R Sidbury, Section Editor)

Pediatric Autoimmune Connective Tissue Diseases: An Update on Disease Characteristics, Associations, and Management

Authors: Alisa Femia, Ruth Ann Vleugels

Published in: Current Dermatology Reports | Issue 4/2013

Login to get access

Abstract

There are several different autoimmune connective tissue diseases that may occur during childhood, each with variable clinical presentations. Gaining familiarity with these disorders and their systemic associations is important, because early therapy may help prevent potentially serious and permanent sequelae. In this review, we discuss the various juvenile autoimmune connective tissue diseases, highlight their clinical manifestations and potential complications, and provide an update on treatment options. In addition, we underline the differences between juvenile and adult-onset autoimmune connective tissue diseases.
Literature
1.
• Dickey BZ, Holland KE, Drolet BA, Galbraith SS, Lyon VB, Siegel DH, et al. Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre. Br J Dermatol. 2013;169(2):428:33. This study provides a recent retrospective review of 53 patients with cutaneous lupus seen in a pediatric dermatology clinic. The authors found that children with discoid lupus erythematosus may be more likely than adults to have associated systemic lupus erythematosus.
2.
Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13(2):171–6.PubMed
3.
Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25–41.
4.
Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.PubMed
5.
Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12(3):444–54.PubMed
6.
Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115(12):1409–15.PubMed
7.
Berry T, Walsh E, Berry R, Desantis E, Smidt AC. Subacute cutaneous lupus erythematosus presenting in childhood: a case report and review of the literature. Pediatr Dermatol. 2012. doi:10.​111/​pde.​12007.
8.
Burch PR, Rowell NR. The sex- and age-distributions of chronic discoid lupus erythematosus in four countries. Possible aetiological and pathogenetic significance. Acta Derm Venereol. 1968;48(1):33–46.PubMed
9.
Bansal C, Ross AS, Cusack CA. Chronic cutaneous lupus in childhood: a report of two cases and review of the literature. Int J Dermatol. 2008;47(5):525–6.PubMed
10.
Wananukul S, Watana D, Pongprasit P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol. 1998;15(5):342–6.PubMed
11.
Janwityanujit S, Totemchokchyakarn K, Verasertniyom O, Vanichapuntu M, Vatanasuk M. Age-related differences on clinical and immunological manifestations of SLE. Asian Pac J Allergy Immunol. 1995;13(2):145–9.PubMed
12.
Vachvanichsanong P, Dissaneewate P. Childhood systemic lupus erythematosus in songklanagarind hospital: a potential unique subgroup. Clin Rheumatol. 1993;12(3):346–9.PubMed
13.
Cherif F, Mebazaa A, Mokni M, El Euch D, Azaiz MI, Dhahri AB. Childhood discoid lupus erythematosus: a Tunisian retrospective study of 16 cases. Pediatr Dermatol. 2003;20(4):295–8.PubMed
14.
Badri T, Khaddar RK, Bouraoui S, Mokni M, Cherif F, Dhahri AB. Discoid lupus erythematosus in an infant. Dermatol Online J. 2005;11(3):38.PubMed
15.
Sampaio MC, de Oliveira ZN, Machado MC, dos Reis VM, Vilela MA. Discoid lupus erythematosus in children—a retrospective study of 34 patients. Pediatr Dermatol. 2008;25(2):163–7.PubMed
16.
Van Gysel D, de Waard-van der Spek FB, de Oranje AP. Childhood discoid lupus erythematosus: report of five new cases and review of the literature. J Eur Acad Dermatol Venereol. 2002;16(2):143–7.PubMed
17.
Callen JP. Discoid lupus erythematosus—variants and clinical associations. Clin Dermatol. 1985;3(3):49–57.PubMed
18.
George PM, Tunnessen Jr WW. Childhood discoid lupus erythematosus. Arch Dermatol. 1993;129(5):613–7.PubMed
19.
Wimmershoff MB, Hohenleutner U, Landthaler M. Discoid lupus erythematosus and lupus profundus in childhood: a report of two cases. Pediatr Dermatol. 2003;20(2):140–5.PubMed
20.
Moises-Alfaro C, Berron-Perez R, Carrasco-Daza D, Gutierrez-Castrellon P, Ruiz-Maldonado R. Discoid lupus erythematosus in children: clinical, histopathologic, and follow-up features in 27 cases. Pediatr Dermatol. 2003;20(2):103–7.PubMed
21.
Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20(3):373–85. v.PubMed
22.
Millard LG, Rowell NR. Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. A long-term follow-up study of 92 patients. Arch Dermatol. 1979;115(9):1055–8.PubMed
23.
• Gronhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335–41. This study is the first nationwide, population-based epidemiologic analysis of cutaneous lupus erythematosus. Pediatric and adult patients were included, and the incidence of cutaneous lupus erythematosus in Sweden was 4/100,000.PubMed
24.
DeSilva TN, Kress DW. Management of collagen vascular diseases in childhood. Dermatol Clin. 1998;16(3):579–92.PubMed
25.
Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol. 1993;28(5 Pt 1):764–70.PubMed
26.
Magana-Garcia M. Antimalarials for children. J Am Acad Dermatol. 1994;30(3):510.PubMed
27.
Miettunen PM, Bruecks A, Remington T. Dramatic response of scarring scalp discoid lupus erythematosus (DLE) to intravenous methylprednisolone, oral corticosteroids, and hydroxychloroquine in a 5-year-old child. Pediatr Dermatol. 2009;26(3):338–41.PubMed
28.
Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford). 2005;44(12):1564–8.
29.
Abe M, Ishikawa O, Miyachi Y. Linear cutaneous lupus erythematosus following the lines of Blaschko. Br J Dermatol. 1998;139(2):307–10.PubMed
30.
Barton LL, Johnson CR. Discoid lupus erythematosus and X-linked chronic granulomatous disease. Pediatr Dermatol. 1986;3(5):376–9.PubMed
31.
Hon KL, Leung AK. Neonatal lupus erythematosus. Autoimmune Dis. 2012;2012:301274.PubMed
32.
Buyon JP, Clancy RM. Neonatal lupus syndromes. Curr Opin Rheumatol. 2003;15(5):535–41.PubMed
33.
Wisuthsarewong W, Soongswang J, Chantorn R. Neonatal lupus erythematosus: clinical character, investigation, and outcome. Pediatr Dermatol. 2011;28(2):115–21.PubMed
34.
Heelan K, Watson R, Collins SM. Neonatal lupus syndrome associated with ribonucleoprotein antibodies. Pediatr Dermatol. 2013;30(4):416–23.
35.
Eftekhari P, Salle L, Lezoualc'h F, Mialet J, Gastineau M, Briand JP, et al. Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol. 2000;30(10):2782–90.PubMed
36.
Admani S, Krakowski AC. Neonatal lupus erythematosus presenting as atypical targetoid-like lesions involving genitals and soles of feet following brief sun exposure. J Clin Aesthet Dermatol. 2013;6(5):19–23.PubMed
37.
Nakajima K, Wakiguchi H, Kodama H, Sano S. Neonatal lupus erythematosus in identical twins, showing transient bullous lesions. Pediatr Dermatol. 2011;28(4):397–400.PubMed
38.
Weston WL, Morelli JG, Lee LA. The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus. J Am Acad Dermatol. 1999;40(5 Pt 1):675–81.PubMed
39.
Gawkrodger DJ, Beveridge GW. Neonatal lupus erythematosus in four successive siblings born to a mother with discoid lupus erythematosus. Br J Dermatol. 1984;111(6):683–7.PubMed
40.
Lee LA. Cutaneous lupus in infancy and childhood. Lupus. 2010;19(9):1112–7.PubMed
41.
Penate Y, Guillermo N, Rodriguez J, Hernandez-Machin B, Montenegro T, Afonso JL, et al. Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review. J Cutan Pathol. 2009;36(6):660–7.PubMed
42.
Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol. 2010;72(3):223–5.PubMed
43.
Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 2007;57(2):261–6.PubMed
44.
Friedman DM, Rupel A, Glickstein J, Buyon JP. Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective. Indian J Pediatr. 2002;69(6):517–22.PubMed
45.
Wojnarowska F. Simultaneous occurrence in identical twins of discoid lupus erythematosus and polymorphic light eruption. J R Soc Med. 1983;76(9):791–2.PubMed
46.
Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31(7):1658–66.PubMed
47.
Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med. 1994;120(7):544–51.PubMed
48.
Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum. 2001;44(8):1832–5.PubMed
49.
Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum. 2001;44(2):487–8.PubMed
50.
• Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76–82. This study examined 257 pregnancies of anti-Ro/SSa positive patients who had previously given birth to children with neonatal lupus and compared 40 patients exposed to hydroxychloroquine to 240 patients unexposed to hydroxychloroquine. The authors found that hydroxychloroquine may help prevent against the recurrence of neonatal lupus erythematosus in subsequent pregnancies.PubMed
51.
Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997;24(1):73–80.PubMed
52.
Vasquez R, Sendejo C, Jacobe H. Morphea and other localized forms of scleroderma. Curr Opin Rheumatol. 2012;24(6):685–93.PubMed
53.
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96.PubMed
54.
Zulian F, Vallongo C, de Oliveira SK, Punaro MG, Ros J, Mazur-Zielinska H, et al. Congenital localized scleroderma. J Pediatr. 2006;149(2):248–51.PubMed
55.
Beltramelli M, Vercellesi P, Frasin A, Gelmetti C, Corona F. Localized severe scleroderma: a retrospective study of 26 pediatric patients. Pediatr Dermatol. 2010;27(5):476–80.PubMed
56.
Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614–20.
57.
• Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012;64(8):1175–85. The authors developed standardized treatment plans for patients with juvenile morphea. It is hoped that these consensus treatment plans will help guide future trials regarding the treatment of juvenile morphea.
58.
Zannin ME, Martini G, Athreya BH, Russo R, Higgins G, Vittadello F, et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol. 2007;91(10):1311–4.PubMed
59.
Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol. 2012;29(6):738–48.PubMed
60.
Nouri S, Jacobe H. Recent developments in diagnosis and assessment of morphea. Curr Rheumatol Rep. 2013;15(2):308.PubMed
61.
El-Kehdy J, Abbas O, Rubeiz N. A review of Parry-Romberg syndrome. J Am Acad Dermatol. 2012;67(4):769–84.PubMed
62.
Saxton-Daniels S, Jacobe HT. An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol. 2010;146(9):1044–5.PubMed
63.
Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873–81.PubMed
64.
Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257–63.PubMed
65.
Stone J. Parry-Romberg syndrome: a global survey of 205 patients using the Internet. Neurology. 2003;61(5):674–6.PubMed
66.
Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology. 2008;71(19):1538–45.PubMed
67.
Amaral TN, Marques Neto JF, Lapa AT, Peres FA, Guirau CR, Appenzeller S. Neurologic involvement in scleroderma en coup de sabre. Autoimmune Dis. 2012;2012:719685.PubMed
68.
Madasamy R, Jayanandan M, Adhavan UR, Gopalakrishnan S, Mahendra L. Parry Romberg syndrome: a case report and discussion. J Oral Maxillofac Pathol. 2012;16(3):406–10.PubMed
69.
Beluffi G, Bassi L, Vitali MC, Meloni G, Caselli D. Parry-Romberg syndrome and odontogenic cyst. A case report. Radiol Med. 2001;101(1–2):88–90.PubMed
70.
Fietta M, Gennari PU. Observations on a case of odontoma of the mandible associated with Parry-Romberg Syndrome. Riv Anat Patol Oncol. 1963;24(SUPPL):763–80.PubMed
71.
O'Flynn S, Kinirons M. Parry-Romberg syndrome: a report of the dental findings in a child followed up for 9 years. Int J Paediatr Dent. 2006;16(4):297–301.PubMed
72.
Fayad S, Steffensen B. Root resorptions in a patient with hemifacial atrophy. J Endod. 1994;20(6):299–303.PubMed
73.
Trainito S, Favero L, Martini G, Pedersen TK, Favero V, Herlin T, et al. Odontostomatologic involvement in juvenile localised scleroderma of the face. J Paediatr Child Health. 2012;48(7):572–6.PubMed
74.
Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50.PubMed
75.
Johnson W, Jacobe H. Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. J Am Acad Dermatol. 2012;67(5):881–9.PubMed
76.
Weibel L, Laguda B, Atherton D, Harper JI. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011;165(6):1308–13.PubMed
77.
Kakimoto CV, Victor Ross E, Uebelhoer NS. En coup de sabre presenting as a port-wine stain previously treated with pulsed dye laser. Dermatol Surg. 2009;35(1):165–7.PubMed
78.
Nijhawan RI, Bard S, Blyumin M, Smidt AC, Chamlin SL, Connelly EA. Early localized morphea mimicking an acquired port-wine stain. J Am Acad Dermatol. 2011;64(4):779–82.PubMed
79.
Rosenkranz ME, Agle LM, Efthimiou P, Lehman TJ. Systemic and localized scleroderma in children: current and future treatment options. Paediatr Drugs. 2006;8(2):85–97.PubMed
80.
• Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol. 2011;64(2):231–42. quiz 43-4. This cross-sectional survey of the Morphea in Adults and Children cohort found that diagnostic delay is common in patients with morphea.PubMed
81.
Vilela FA, Carneiro S, Ramos-e-Silva M. Treatment of morphea or localized scleroderma: review of the literature. J Drugs Dermatol. 2010;9(10):1213–9.PubMed
82.
•• Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006. This recent, randomized, double-blind, placebo-controlled trial found that methotrexate is efficacious and well-tolerated amongst patients with juvenile morphea.PubMed
83.
Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012;39(2):286–94.PubMed
84.
• Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O'Neil KM. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol. 2010;37(1):175–81. This survey of pediatric rheumatologists in North America found that while most use methotrexate and corticosteroids for juvenile morphea, there was wide variability in terms of specific treatment regimens.PubMed
85.
• Zulian F, Vallongo C, Patrizi A, Belloni-Fortina A, Cutrone M, Alessio M, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–6. Long-term follow-up of patients previously enrolled in a randomized, double-blind, placebo-controlled trial of methotrexate in juvenile morphea found that methotrexate was beneficial and well-tolerated in the long-term.PubMed
86.
Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford). 2009;48(11):1410–3.
87.
Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011;65(5):925–41.PubMed
88.
Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21(11):2143–6.PubMed
89.
Foeldvari I, Tyndall A, Zulian F, Muller-Ladner U, Czirjak L, Denton C, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012;51(10):1832–7.
90.
Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971–8.PubMed
91.
Garty BZ, Athreya BH, Wilmott R, Scarpa N, Doughty R, Douglas SD. Pulmonary functions in children with progressive systemic sclerosis. Pediatrics. 1991;88(6):1161–7.PubMed
92.
Hatta Y, Hasegawa M, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Mod Rheumatol. 2013. doi:10.​1007/​s10165-013-0884-1.
93.
Hasegawa M, Hatta Y, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Mod Rheumatol. 2012. doi:10.​1007/​s10165-012-0764-0.
94.
Foeldvari I. Update on pediatric systemic sclerosis: similarities and differences from adult disease. Curr Opin Rheumatol. 2008;20(5):608–12.PubMed
95.
Duffy CM, Laxer RM, Lee P, Ramsay C, Fritzler M, Silverman ED. Raynaud syndrome in childhood. J Pediatr. 1989;114(1):73–8.PubMed
96.
Zulian F, Woo P, Athreya BH, Laxer RM, Medsger Jr TA, Lehman TJ, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203–12.PubMed
97.
Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5.PubMed
98.
Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007;57(6):937–43.PubMed
99.
Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26–30.PubMed
100.
Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363–73.PubMed
101.
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. British journal of cancer. 2001;85(1):41–5.PubMed
102.
Clemente G, Piotto DG, Barbosa C, Peracchi OA, Len CA, Hilario MO, et al. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. Rev Bras Reumatol. 2012;52(4):549–53.PubMed
103.
Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87(2):70–86.
104.
Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59(5):677–85.PubMed
105.
Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297–301.PubMed
106.
• Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol. 2010;146(7):729–38. In this retrospective cohort study of patients with both classic and skin-predominant dermatomyositis, the authors found a 23% prevalence of interstitial lung disease. The prevalence did not differ between patients with classic and skin-predominant dermatomyositis and decreased diffusing capacity for carbon monoxide was a sensitive screen for interstitial lung disease.PubMed
107.
• Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72. This multinational, multicenter study of 490 patients with juvenile dermatomyositis found that although functional outcomes of patients have improved when compared with earlier literature, 40.7% of patients had decreased functional ability, and 6.5% had major impairment at cross-sectional assessment.
108.
Morinishi Y, Oh-Ishi T, Kabuki T, Joh K. Juvenile dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol. 2007;17(5):413–7.PubMed
109.
Chiu SK, Yang YH, Wang LC, Chiang BL. Ten-year experience of juvenile dermatomyositis: a retrospective study. J Microbiol Immunol Infect. 2007;40(1):68–73.PubMed
110.
Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary–clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39(3):223–32.PubMed
111.
Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39(6):632–6.
112.
Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012;41(1):50–8.PubMed
113.
Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol. 2012. doi:10.​1002/​pp01.​22742.
114.
Sanner H, Aalokken TM, Gran JT, Sjaastad I, Johansen B, Flato B. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(1):86–91.PubMed
115.
Trapani S, Camiciottoli G, Vierucci A, Pistolesi M, Falcini F. Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford). 2001;40(2):216–20.
116.
Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637–44.PubMed
117.
Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford). 2009;48(12):1541–7.
118.
Sanner H, Kirkhus E, Merckoll E, Tollisen A, Roisland M, Lie BA, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res (Hoboken). 2010;62(8):1103–11.
119.
Gutierrez Jr A, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther. 2012;25(2):195–206.PubMed
120.
Walsh JS, Fairley JA. Calcifying disorders of the skin. J Am Acad Dermatol. 1995;33(5 Pt 1):693–706. quiz 7-10.PubMed
121.
Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol. 2011;65(1):1–12. quiz 3-4.PubMed
122.
Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882–8.PubMed
123.
Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005;34(6):805–12.PubMed
124.
Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341–51.PubMed
125.
Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–9.PubMed
126.
Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425–35.PubMed
127.
• Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol. 2012;148(4):455–62. This retrospective review of 78 patients with calcinosis cutis and autoimmune connective tissue disease found that systemic sclerosis and dermatomyositis were the most likely autoimmune connective tissue diseases to have associated calcinosis. Surgical excision provided superior results to medical therapy alone, and diltiazem provided the best results compared with other medical therapies.PubMed
128.
Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25(6):1198–204.PubMed
129.
Lang B, Dooley J. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. J Pediatr. 1996;128(3):429–32.PubMed
130.
Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol. 2011;65(1):15–22. quiz 3-4.PubMed
131.
Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. does diltiazem induce its regression? Ann Rheum Dis. 1998;57(4):252–4.PubMed
132.
Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763–6.PubMed
133.
Touimy M, Janani S, Rachidi W, Etaouil N, Mkinsi O. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine. 2013;80(1):108–9.PubMed
134.
Kalajian AH, Perryman JH, Callen JP. Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol. 2009;145(3):334. author reply 5.PubMed
135.
Eddy MC, Leelawattana R, McAlister WH, Whyte MP. Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab. 1997;82(11):3536–42.PubMed
136.
Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22(7):1300–3.PubMed
137.
Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.PubMed
138.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.PubMed
139.
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.PubMed
140.
Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol. 2009;36(12):2704–10.PubMed
141.
Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011;165(6):1273–9.PubMed
142.
Callen JP, Hyla JF, Bole Jr GG, Kay DR. The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol. 1980;116(3):295–8.PubMed
143.
Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol. 2010;32(3):189–91.PubMed
144.
Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161(4):854–60.PubMed
145.
Kozu KT, Silva CA, Bonfa E, Sallum AM, Pereira RM, Viana VS, et al. Dyslipidaemia in juvenile dermatomyositis: the role of disease activity. Clin Exp Rheumatol. 2013;31(4):638–44.
146.
Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum. 2006;55(4):564–8.PubMed
147.
Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, et al. Lipodystrophy in patients with juvenile dermatomyositis–evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28(3):610–5.PubMed
148.
Charalabopoulos K, Charalabopoulos A, Papaioannides D. Diabetes mellitus type I associated with dermatomyositis: an extraordinary rare case with a brief literature review. BMJ Case Rep. 2009;2009.
149.
Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga A. Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases. Pediatr Dermatol. 1996;13(6):477–82.PubMed
150.
Schwartz T, Sanner H, Husebye T, Flato B, Sjaastad I. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(5):766–71.PubMed
151.
Eimer MJ, Brickman WJ, Seshadri R, Ramsey-Goldman R, McPherson DD, Smulevitz B, et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr. 2011;159(5):795–801.PubMed
152.
Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;14(4)291–313.
153.
Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545–7.PubMed
154.
Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–8.PubMed
155.
Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138–41.PubMed
156.
Dagher R, Desjonqueres M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–6.PubMed
157.
Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446–51.
158.
Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089–94.PubMed
159.
Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59(7):989–95.PubMed
160.
Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol. 2002;14(6):658–62.PubMed
161.
Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol. 1998;2(4):205–11.PubMed
162.
Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila). 1987;26(11):561–6.
163.
Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol. 1996;23(8):1424–7.PubMed
164.
Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Medicina clinica. 2006;127(18):697–701.PubMed
165.
Modesto CBM, Marsal S, Arnal-Guimera C. FK-506 in the treatment of unresponsive juvenile dermatomyositis. Ann Rheum Dis. 2000;59:728.
166.
Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491–6.
167.
Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.PubMed
168.
Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107–11.PubMed
169.
•• Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24. This randomized, double-blind placebo-phase trial failed to demonastrate a significant benefit of rituximab for the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis.PubMed
170.
• Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953–61. This survey of North American pediatric rheumatologists found that while most physicians utilized corticosteroids and methotrexate for the treatment of juvenile dermatomyositis, there was varability in the route of administration of corticosteroids, and in the use of hydroxychloroquine and intravenous immunoglobulin.PubMed
171.
• Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546–53. This report describes the results of a consensus meeting of 30 pediatric rheumatologists and 4 lay participants convening to establish consensus treatment plans for patients with moderate juvenile dermatomyositis. It is hoped that the results will help guide future trials regarding treatment of juvenile dermatomyositis.
Metadata
Title
Pediatric Autoimmune Connective Tissue Diseases: An Update on Disease Characteristics, Associations, and Management
Authors
Alisa Femia
Ruth Ann Vleugels
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 4/2013
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-013-0058-6

Other articles of this Issue 4/2013

Current Dermatology Reports 4/2013 Go to the issue

Pediatrics (R Sidbury, Section Editor)

Pityriasis Lichenoides and Cutaneous T Cell Lymphoma: An Update on the Diagnosis and Management of the Most Common Benign and Malignant Cutaneous Lymphoproliferative Diseases in Children

Pregnancy Dermatoses and Fetal Exposure (A Ingber, Section Editor)

Autoimmune Progesterone Dermatitis

Pediatrics (R Sidbury, Section Editor)

Pediatric Dermatology Clinical-Pathologic Case “Mimickers”

Pediatrics (R Sidbury, Section Editor)

Pearls from Medical Genetics Clinic

Pregnancy Dermatoses and Fetal Exposure (A Ingber, Section Editor)

Urticaria and Angioedema in Pregnancy

Pregnancy Dermatoses and Fetal Exposure (A Ingber, Section Editor)

Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women